Susanne Smithson
Family · Boynton Beach, FLNPI 1851874069
Payments from drug & device makers
Across 179 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$473
- Novo Nordisk$399
- Lilly USA, LLC$381
- AstraZeneca$377
- Bayer$227
- Amgen$208
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,165100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $473 |
| Novo Nordisk | 28 | $399 |
| Lilly USA, LLC | 24 | $381 |
| AstraZeneca | 20 | $377 |
| Bayer | 16 | $227 |
| Amgen | 13 | $208 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $162 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $154 |
| Exact Sciences | 6 | $142 |
| GSK | 4 | $85 |
| Eisai Inc. | 3 | $79 |
| Boehringer Ingelheim | 3 | $74 |
| Optinose US, Inc. | 3 | $67 |
| Idorsia Pharmaceuticals US Inc | 3 | $66 |
| Esperion Therapeutics, Inc. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Pfizer | 2 | $35 |
| Noven Therapeutics, LLC | 1 | $22 |
| Lundbeck LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
How this compares
$3,165 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $37,561 |
| MounjaroTirzepatide | 32 | $34,904 |
| WegovySemaglutide | 11 | $17,855 |
| FarxigaDapagliflozin Propanediol | 17 | $13,155 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $1,603 |
| Levothyroxine Sodium | 80 | $1,120 |
| Doxycycline Hyclate | 107 | $972 |
| Levocetirizine Dihydrochloride | 89 | $972 |
| Fluticasone Propionate | 79 | $907 |
| Zolpidem Tartrate | 35 | $771 |
| Valsartan | 15 | $761 |
| Omeprazole | 33 | $720 |
| Methylprednisolone | 96 | $655 |
| Bupropion XlBupropion Hcl | 19 | $646 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 53 | $601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $399 | $55,41639 claims |
| Lilly USA, LLCMounjaro | $381 | $34,90432 claims |
| AstraZenecaFarxiga | $377 | $13,15517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Boynton Beach
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.